RecruitingObesityOverweight
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
Eligible age
18–99 yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The main objective of this study is to assess participants' ability to self-administer subcutaneous doses of maridebart cafraglutide at home using an autoinjector device.
Sponsor: Amgen
You may qualify if…
- ✓ Body mass index (BMI) ≥ 30 kilograms per meter square (kg/m\^2), or BMI ≥ 27 to \< 30 kg/m\^2 with one of the following:
- ✓ hypertension: treated, or with systolic blood pressure ≥ 130 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 80 mmHg
- ✓ dyslipidemia: treated or previously diagnosed high cholesterol, high triglycerides, or low HDL cholesterol.
- ✓ history of obstructive sleep apnea
- ✓ history of cardiovascular disease
- ✓ history of fatty liver disease (including metabolic dysfunction-associated steatotic liver disease \[MASLD\] or metabolic dysfunction-associated steatohepatitis \[MASH\])
- ✓ At least 1 unsuccessful attempt at weight loss by diet and exercise.
- ✓ Contraception for females.
You may not qualify if…
- ✕ Obesity induced by other endocrinologic disorders.
- ✕ Change in body weight \> 5 kg within last 90 days.
- ✕ Previous or planned surgical, endoscopic, or device-based treatment for obesity.
- ✕ History of malignancy within the past 5 years.
- ✕ Type 1 or Type 2 diabetes mellitus.
- ✕ History of chronic pancreatitis or history of acute pancreatitis within last 180 days.
- ✕ Family or personal history of medullary thyroid cancer.
- ✕ Previous participation in a Maridebart Cafraglutide trial.
Where it's recruiting
California
San Diego
Florida
Miami · Orlando · The Villages
Georgia
Johns Creek · Woodstock
Idaho
Meridian
Illinois
Oak Brook
Maryland
Bowie
New York
Rochester
North Carolina
Morehead City
Ohio
Columbus
Oklahoma
Chickasha
South Carolina
Greenville
Texas
Dallas · Denison · DeSoto · Houston …
Source: ClinicalTrials.gov · NCT07871409 · last updated 2026-11-09